Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 19/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 19/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 19/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 18/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 17/20 | 1.00 |
| ▸ | BRS3 | P32247 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650010 | 0.88 | CYP2E1 (1.00) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL8277910 | 0.85 | CYP2E1 (0.74) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL15693609 | 0.85 | CYP2D6 (0.73) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL2734131 | 0.84 | CYP2E1 (1.00) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL1064755 | 0.83 | CYP2E1 (0.82) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL15693657 | 0.83 | CYP2E1 (0.71) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL15693611 | 0.83 | RAB9A (0.76) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| Bromide SCHEMBL1064752 | 0.83 | CYP2E1 (0.80) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL6481746 | 0.81 | CYP2E1 (0.76) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL15693642 | 0.81 | RAB9A (0.76) | CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118739252-B | Grid-connected simulation model of electrochemical energy storage power station and construction method thereof | 国网甘肃省电力公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119086900-A | Based on m7G RNA methylation and copper death related protein lung adenocarcinoma diagnosis marker and screening method thereof | 上海市胸科医院 | 2024-12-06 | — | — | CN | claimed |
| CN-118983881-A | Control method of grid-built inverter with signal-to-signal transmission function | 龙源(北京)新能源工程技术有限公司 | 2024-11-19 | — | — | CN | claimed |
| US-12129274-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2024-10-29 | — | — | US | claimed |
| CN-118739252-A | Grid-connected simulation model of electrochemical energy storage power station and construction method thereof | 国网甘肃省电力公司 | 2024-10-01 | — | — | CN | claimed |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | REVAGENIX, INC. | 2023-06-01 | — | — | US | claimed |
| CN-111511406-B | Challenge test for diagnosing autism spectrum disease subtypes | 斯大利卡拉公司 | 2023-04-28 | — | — | CN | claimed |
| US-20220411456-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | REVAGENIX, INC. (US) | 2022-12-29 | — | — | US | claimed |
| CN-112448807-B | Conservative digital chaos-based OFDM-PON physical layer encryption method for three-dimensional Arnold transformation | 杭州电子科技大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114240012-A | Method for calculating optimal energy flow of comprehensive energy distribution system | 国网山西省电力公司经济技术研究院 | 2022-03-25 | — | — | CN | claimed |
| CN-122006607-A | Natural plant compound microcapsule for aquatic product transportation and keep-alive and application thereof | 泰山学院 | 2026-05-12 | — | — | CN | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260116957-A1 | PHARMACEUTICAL COMPOSITION FOR AMELIORATING ACUTE LUNG INJURY AND ACUTE WORSENING OF PULMONARY FIBROSIS | UNIV MIE (JP) | 2026-04-30 | — | — | US | disclosed |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| CN-114240012-A | Method for calculating optimal energy flow of comprehensive energy distribution system | 国网山西省电力公司经济技术研究院 | 2022-03-25 | — | — | CN | disclosed |
| CN-114214418-A | Biomarker for evaluating sensitivity of lung cancer patient to proton radiotherapy and application thereof | 上海交通大学医学院附属第九人民医院 | 2022-03-22 | — | — | CN | disclosed |
| US-11281857-B1 | Composite slot type resolution | AMAZON TECHNOLOGIES, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11274078-B2 | Drug for treating tumor diseases and having antibacterial antivirus anti-inflammatory effects | SHI JIANYOU (CN) | 2022-03-15 | — | — | US | disclosed |
| US-20220073788-A1 | Adhesive-Backed Composite Film | 3M INNOVATIVE PROPERTIES COMPANY | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | CYP2E1 494/4885CYP2C8 988/4885CYP2D6 439/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | CYP2E1 310/4885CYP2C8 976/4885CYP2D6 527/4885 |
| US-11274078-B2 | Drug for treating tumor diseases and having antibacterial antivirus anti-inflammatory effects | NFKBIA, TNF, CHUK | CYP2E1 2386/4885CYP2C8 800/4885CYP2D6 1920/4885 |
| US-12129274-B2 | Modular synthesis of aminoglycosides | MRPL21, COASY, AARS1 | CYP2E1 4209/4885CYP2C8 2291/4885CYP2D6 2021/4885 |
| US-20230167148-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | MRPL21, COASY, AARS1 | CYP2E1 4209/4885CYP2C8 2291/4885CYP2D6 2021/4885 |
| US-20220411456-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | MRPL21, COASY, AARS1 | CYP2E1 4209/4885CYP2C8 2291/4885CYP2D6 2021/4885 |
| US-12599593-B2 | Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers | MOK, TTK, MAPK4 | CYP2E1 3779/4885CYP2C8 3341/4885CYP2D6 3682/4885 |
| US-20260116957-A1 | PHARMACEUTICAL COMPOSITION FOR AMELIORATING ACUTE LUNG INJURY AND ACUTE WORSENING OF PULMONARY FIBROSIS | FIBP, VIP, VSIG8 | CYP2E1 4538/4885CYP2C8 3824/4885CYP2D6 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.